Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

OBJECTIVES:

- To determine whether early myocardial structural and functional changes can be detected
using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin
lymphoma receiving doxorubicin hydrochloride-based chemotherapy.

OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of
doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of
chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin
lymphoma.

DISEASE CHARACTERISTICS:

- Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma

- Newly diagnosed disease

- Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the
University of Nebraska Medical Center

PATIENT CHARACTERISTICS:

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No pacemaker

- No chronic kidney disease stages 3-5 (glomerular filtration rate < 60 mL/min)

- Able to lie flat for 90 minutes

- No metallic foreign body not approved for MRI

- No known hypersensitivity to gadolinium contrast or other required drugs in the study

- No comorbidity or condition which, in the opinion of the investigator, may interfere
with the assessments and procedures of this study

- Able to fulfill the requirements of the study

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior chemotherapy

- No prior radiotherapy to mantle or mediastinum